Skip to main content
SpringerLink
Log in

The Treatment of Atrial Fibrillation

An Evaluation of Drug Therapy, Electrical Modalities and Therapeutic Considerations

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice, and is responsible for considerable morbidity. Basic studies have shown that AF is usually due to the coexistence of multiple functional atrial re-entry circuits, and that the main determinant of its haemodynamic manifestations is the ventricular response rate. The major adverse clinical consequences of AF include palpitations, impaired cardiac function and thromboembolism.

One approach to treating AF is to convert the patient’s cardiac rhythm to sinus rhythm by direct current electrical cardioversion, which is initially successful in about 90% of cases. However, the AF recurrence rate over the year subsequent to cardioversion is very high, in the order of 75% in patients receiving no drug therapy. Class I and class III antiarrhythmic drugs reduce the rate of recurrence of AF, but at the expense of a variety of potential adverse effects including ventricular proarrhythmia. The latter is a rare effect (occurring in 1 to 2% of patients receiving most drugs), but can be lethal.

A second approach to therapy is to leave the patient in AF, but to control the ventricular response rate and to prevent thromboemboli with oral anticoagulants. Disadvantages of this approach include the possibilities of functional limitations imposed by the arrhythmia, adverse effects of drug therapy, and major bleeding related to anticoagulation.

New approaches currently under study include surgery to prevent AF from sustaining itself, implantable cardioverter devices to maintain sinus rhythm, and modification of AV nodal function by the induction of controlled radiofrequency injury.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pritchett ELC. Management of atrial fibrillation. N Engl J Med 1992; 326: 1264–71

    Article  PubMed  CAS  Google Scholar 

  2. Zipes DP. Specific arrhythmias: diagnosis and treatment. Braun-wald E: Heart Disease, A textbook of Cardiovascular Medicine, Saunders, 1992: 667-725

  3. Hoffa M, Ludwig C. Einige neue Versuche üher Herzbewegung. Z Rationale Med 1850; 9: 107–44

    Google Scholar 

  4. Vulpian A. Note sur les effets de la faradisation directe des ventricules du coeur chez le chien. Arch Physiol 1874; 1: 975–80

    Google Scholar 

  5. Cushny AR. On the interpretation of pulse-tracings. J Exp Med 1899; 4: 327–47

    Article  PubMed  CAS  Google Scholar 

  6. Fredericq L. Rythme affolé des ventricules dü à la fibrillation des oreillettes: physiologie du faisceau auriculo-ventriculaire. Arch Int Physiol 1904; 5: 281–5

    Google Scholar 

  7. Garrey WE. The nature of fibrillary contraction of the heart: its relation to tissue mass and form. Am J Physiol 1914; 33: 397–414

    Google Scholar 

  8. Rothberger CJ, Winterberg H. Über Vorhofflimmern und Vorhofflattern. Pflügers Arch 1914; 160: 42–90

    Article  Google Scholar 

  9. Lewis T, Drury AN, Wedd AM, et al. Observations upon the action of certain drugs upon fibrillation of the auricles. Heart 1922; 9: 207–67

    CAS  Google Scholar 

  10. Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther 1962; 140: 183–8

    Google Scholar 

  11. Allessie MA, Lammers WJEP, Bonke FIM, et al. Experimental evaluation of Moe’s multiple wavelet hypothesis of atrial fibrillation. In: Zipes DP, Jalife J, editors. Cardiac arrhythmias. Philadelphia: Grune & Stratton, 1985: 265-76

  12. Allessie MA, Bonke FIM, Schopman FJG. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The ‘leading circle’ concept: a new model of circus movement in cardiac tissue without the involvement of an anatomic obstacle. Circ Res 1977; 41: 9–18

    CAS  Google Scholar 

  13. Allessie MA, Lammers WJEP, Bonke FIN, et al. Intraatrial reentry as a mechanism for atrial flutter by acetylcholine and rapid pacing in the dog. Circulation 1984; 70: 123–35

    Article  PubMed  CAS  Google Scholar 

  14. Rensma PL, Allessie MA, Lammers WJEP, et al. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988; 62: 395–410

    Article  PubMed  CAS  Google Scholar 

  15. Smeets JLRM, Allessie MA, Lammers WJEP, et al. The wavelength of the cardiac impulse and reentrant arrhythmias in isolated rabbit atrium. Circ Res 1986; 58: 96–108

    Article  PubMed  CAS  Google Scholar 

  16. Wiener N, Rosenblueth A. The mathematical formulation of the problem of conduction of impulses in a network of connected excitable elements, specifically in cardiac muscle. Arch Inst Cardiol Mex 1946; 16: 205–65

    PubMed  CAS  Google Scholar 

  17. Viko LE, Marvin HM, White PD. A clinical report on the use of quinidin sulphate. Arch Int Med 1923; 31: 345–63

    Article  Google Scholar 

  18. Andrus EC, Carter EP. The refractory period of the normally-beating dog’s auricle; with a note on the occurrence of auricular fibrillation following a single stimulus. J Exp Med 1930; 51: 357–68

    Article  PubMed  CAS  Google Scholar 

  19. Burn JH, Vaughan Williams EM, Walker JM. The effects of acetylcholine in the heart-lung preparation including the production of auricular fibrillation. J Physiol 1955; 128: 277–93

    PubMed  CAS  Google Scholar 

  20. Hoff HE, Geddes LA. Cholinergic factor in auricular fibrillation. J Appl Physiol 1955; 8: 177–91

    PubMed  CAS  Google Scholar 

  21. Coumel P. Role of the autonomic nervous system in paroxysmal atrial fibrillation. In: Touboul P, Waldo AL, editors. Atrial Arrhythmias: Current Concepts and Management. St. Louis: Mosby-Year Book, 1990: 248-61

  22. Wang Z, Pagé P, Nattel S. Mechanism of flecainide’s antiarrhythmic action in experimental atrial fibrillation. Circ Res 1992; 71: 271–87

    Article  PubMed  CAS  Google Scholar 

  23. Wang J, Bourne GW, Wang Z, et al. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation: the importance of use-dependent effects on refractoriness. Circulation 1993; 88: 1030–44

    Article  PubMed  CAS  Google Scholar 

  24. Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation: differences in reverse use-dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation. In press

  25. Josephson ME. Atrial flutter and fibrillation. In: Clinical cardiac electrophysiology: techniques and interpretations. Philadelphia: Lea & Febiger, 1993: 275-310

  26. Kannel WB, Abbott RD, Savage DD, et al. Epidemiological features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982; 306: 1018–22

    Article  PubMed  CAS  Google Scholar 

  27. Wolf PA, Kannel WB, McGee DL, et al. Duration of atrial fibrillation and imminence of stroke: the Framingham Study. Stroke 1983; 14: 665–7

    Google Scholar 

  28. Bailey D, Lehmann MH, Schumacher DN, et al. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation [abstract]. J Am Coll Cardiol 1992; 19: 41A

    Google Scholar 

  29. Gesell RA. Auricular systole and its relation to ventricular output. Am J Physiol 1911; 29: 32–63

    Google Scholar 

  30. Gesell R. The effects of change in auricular tone and amplitude of auricular systole on ventricular output. Am J Physiol 1915; 38: 404–13

    Google Scholar 

  31. Rahimtoola SH, Ehsani A, Sinno MZ, et al. Left atrial transport function in myocardial infarction: importance of its booster pump function. Am J Med 1975; 59: 686–94

    Article  PubMed  CAS  Google Scholar 

  32. Greenberg B, Chatterjee K, Parmley WW, et al. The influence of left ventricular filling pressure on atrial contribution to cardiac output. Am Heart J 1979; 98: 742–51

    Article  PubMed  CAS  Google Scholar 

  33. Karlöf I. Haemodynamic effect of atrial triggered versus fixed rate pacing at rest and during exercise in complete heart block. Acta Med Scand 1975; 197: 195–206

    PubMed  Google Scholar 

  34. Ausubel K, Steingart RM, Shimshi M, et al. Maintenance of exercise stroke volume during ventricular versus atrial synchronous pacing: role of contractility. Circulation 1985; 72: 1037–43

    Article  PubMed  CAS  Google Scholar 

  35. Benchimol A, Lowe HM, Akre PR. Cardiovascular response to exercise during atrial fibrillation and after conversion to sinus rhythm. Am J Cardiol 1965; 16: 31–41

    Article  PubMed  CAS  Google Scholar 

  36. Hansen WR, McClendon RL, Kinsman JM. Auricular fibrillation. Hemodynamic studies before and after conversion with quinidine. Am Heart J 1952; 44: 499–516

    CAS  Google Scholar 

  37. Kahn DR, Wilson WS, Weber W, et al. Hemodynamic studies before and after cardioversion. J Thorac Cardiovasc Surg 1964; 48: 898–902

    PubMed  CAS  Google Scholar 

  38. Killip T, Baer RA. Hemodynamic effects after reversion from atrial fibrillation to sinus rhythm by precordial shock. J Clin Invest 1966; 45: 658–71

    Article  PubMed  CAS  Google Scholar 

  39. Resnekov L. Haemodynamic studies before and after electrical conversion of atrial fibrillation and flutter to sinus rhythm. Br Heart J 1967; 29: 700–8

    Article  PubMed  CAS  Google Scholar 

  40. Shapiro W, Klein G. Alterations in cardiac function immediately following electrical conversion of atrial fibrillation to normal sinus rhythm. Circulation 1968; 38: 1074–84

    Article  PubMed  CAS  Google Scholar 

  41. Lipkin DP, Frenneaux M, Stewart R, et al. Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm. Br Heart J 1988; 59: 572–7

    Article  PubMed  CAS  Google Scholar 

  42. Coleman HN, Taylor RR, Pool PE, et al. Congestive heart failure following chronic tachycardia. Am Heart J 1971; 81: 790–8

    Article  PubMed  Google Scholar 

  43. Riegger AJG, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin Sci 1982; 62: 465–9

    PubMed  CAS  Google Scholar 

  44. Gosselink ATM, Crijns HJGM, Hamer HPM, et al. Changes in left and right atrial size after cardioversion of atrial fibrillation: role of mitral valve disease. J Am Coll Cardiol 1993; 22: 1666–72

    Article  PubMed  CAS  Google Scholar 

  45. Hassam R, Koutsounis H. Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias. PACE 1993; 16: 1275–84

    Article  PubMed  Google Scholar 

  46. Rodriguez LM, Smeets JLRM, Xie B, et al. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993; 72: 1137–41

    Article  PubMed  CAS  Google Scholar 

  47. Van Gelder IC, Crijns HJGM, Blanksma PK, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unasso-ciated with cardiac valve disease. Am J Cardiol 1993; 72: 560–6

    Article  PubMed  Google Scholar 

  48. Leistad E, Christensen G, Ilebekk A, et al. Atrial contractile performance after cessation of atrial fibrillation. Am J Physiol 1993; 264: H104–H9

    PubMed  CAS  Google Scholar 

  49. Sanfilippo AJ, Abascal VM, Sheehan M, et al. Atrial enlargement as a consequence of atrial fibrillation: a prospective echocardiographic study. Circulation 1990; 82: 792–7

    Article  PubMed  CAS  Google Scholar 

  50. Morillo CA, Klein GJ, Jones DL. Experimental atrial fibrillation: evidence for a focal mechanism [abstract]. J Am Coll Cardiol 1993; 21: 183A

    Google Scholar 

  51. Wijffels M, Kirchhof C, Frederiks J, et al. Atrial fibrillation begets atrial fibrillation [abstract]. Circulation 1993; 88: 1–18

    Google Scholar 

  52. Coulshed N, Epstein EJ, MacKendrick CS, et al. Systemic embolism in mitral valve disease. Br Heart J 1970; 32: 26–34

    Article  PubMed  CAS  Google Scholar 

  53. Daley R, Mattingly TW, Holt CL, et al. Systemic arterial embolism in rheumatic heart disease. Am Heart J 1951; 42: 566–81

    Article  PubMed  CAS  Google Scholar 

  54. Graham GK, Taylor JA, Ellis LB, et al. Studies in mitral stenosis. II. A correlation of post-mortem findings with the clinical course of the disease in one hundred and one cases. Arch Intern Med 1951; 88: 532–47

    CAS  Google Scholar 

  55. Hinton RC, Kistler JP, Fallon JT, et al. Influence of etiology of atrial fibrillation on incidence of systemic embolism. Am J Cardiol 1977; 40: 509–13

    Article  PubMed  CAS  Google Scholar 

  56. Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol 1986; 43: 71–84

    Article  Google Scholar 

  57. Peterson P, Madsen EB, Brun B, et al. Silent cerebral infarction in chronic atrial fibrillation. Stroke 1987; 18: 1098–1100

    Article  Google Scholar 

  58. Wolf PA, Dawber TR, Thomas E Jr, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Fra-mingham Study. Neurology 1978; 28: 973–7

    Article  PubMed  CAS  Google Scholar 

  59. Dunn M, Alexander J, deSilva R, et al. Antithrombotic therapy in atrial fibrillation. Chest 1989; 95: 118S–125S

    Article  PubMed  CAS  Google Scholar 

  60. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. clinical features of patients at risk. Ann Int Med 1992; 116: 1–5

    Google Scholar 

  61. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. echocardiographic features of patients at risk. Ann Int Med 1992; 116: 6–12

    Google Scholar 

  62. Corbalán R, Arriagada D, Braun S, et al. Risk factors for systemic embolism in patients with paroxysmal atrial fibrillation. Am Heart J 1992; 124: 149–53

    Article  PubMed  Google Scholar 

  63. Moulton AW, Singer DE, Haas JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. Am J Med 1991; 91: 156–61

    Article  PubMed  CAS  Google Scholar 

  64. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med 1987; 317: 669–74

    Article  PubMed  CAS  Google Scholar 

  65. Brand FN, Abbott RD, Kannel WB, et al. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham study. JAMA 1985; 254: 3449–53

    Article  PubMed  CAS  Google Scholar 

  66. Cameron A, Schwartz MJ, Kronmal RA. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol 1988; 61: 714–7

    Article  PubMed  CAS  Google Scholar 

  67. Kannel WB, Abbott RD, Savage DD, et al. Coronary heart disease and atrial fibrillation: the Framingham study. Am Heart J 1983; 106: 389–96

    Article  PubMed  CAS  Google Scholar 

  68. Carson PE, Johnson GR, Dunkman B, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: the V-HeFT studies. Circulation 1993, 87 Suppl. VI: VI102-10

  69. Davidson E, Weinberger I, Rotenberg Z, et al. Atrial fibrillation: cause at time of onset. Arch Intern Med 1989; 149: 457–9

    Article  PubMed  CAS  Google Scholar 

  70. Robinson K, Rowland E, Krikler DM. Wolff-Parkinson-White syndrome: atrial fibrillation as the presenting arrhythmia. Br Heart J 1988; 59: 578–80

    Article  PubMed  CAS  Google Scholar 

  71. Bar-Sela S, Ehrenfeld M, Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 1981; 141: 1191–2

    Article  PubMed  CAS  Google Scholar 

  72. Fleischer N, Sonnenblick EH, Fein FS. The heart and endocrine disease. In: Rackley CE, Sonnenblick EH, Wenger NK, editors. The heart arteries and veins. New York: McGraw-Hill Information Services Company, 1990: 1497-513

  73. Ciaccheri M, Cecchi F, Arcangeli C, et al. Occult thyrotoxicosis in patient with chronic and paroxysmal isolated atrial fibrillation. Clin Cardiol 1984; 7: 413–6

    PubMed  CAS  Google Scholar 

  74. Lowenstein SR, Gabow PA, Cramer J, et al. The role of alcohol in new-onset atrial fibrillation. Arch Intern Med 1983; 143: 1882–5

    Article  PubMed  CAS  Google Scholar 

  75. Davidson E, Rotenberg Z, Weinberger I, et al. Diagnosis and characteristics of lone atrial fibrillation. Chest 1989; 95: 1048–50

    Article  PubMed  CAS  Google Scholar 

  76. Frustaci A, Caldarulo M, Buffon A, et al. Cardiac biopsy in patients with ‘Primary’ atrial fibrillation: histologic evidence of occult myocardial diseases. Chest 1991; 100: 303–6

    Article  PubMed  CAS  Google Scholar 

  77. Guiraudon CM, Ernst NM, Guiraudon GM, et al. The pathology of drug resistant lone atrial fibrillation in eleven surgically treated patients. In: Kingma JH, van Hemel, Lie KI, editors. Atrial fibrillation, a treatable disease? Netherlands: Kluwer Academic Publishers, 1992: 41-58

  78. Donovan KD, Dobb GJ, Coombs LJ, et al. Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecain-ide. Am J Cardiol 1991; 67: 137–41

    Article  PubMed  CAS  Google Scholar 

  79. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992; 70: 69–72

    Article  PubMed  CAS  Google Scholar 

  80. Lown B, Perlroth MG, Kaidbey S, et al. ‘Cardioversion’ of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients. N Engl J Med 1963; 269: 325–31

    Article  PubMed  CAS  Google Scholar 

  81. Dalzell GW, Anderson J, Adgey AA. Factors determining success and energy requirements for cardioversion of atrial fibrillation. Q J Med 1990; 76: 903–13

    PubMed  CAS  Google Scholar 

  82. Lundstrom T, Ryden L. Chronic atrial fibrillation: long-term results of direct current conversion. Acta Med Scand 1988; 223: 53–9

    Article  PubMed  CAS  Google Scholar 

  83. Kowey PR. The calamity of cardioversion of conscious patients. Am J Cardiol 1988; 61: 1106–7

    Article  PubMed  CAS  Google Scholar 

  84. Wiggers CJ, Wegria R. Ventricular fibrillation due to single, localized induction and condenser shocks applied during the vulnerable phase of ventricular systole. Am J Physiol 1921; 128: 500–5

    Google Scholar 

  85. Falk RH, Podrid PJ. Electrical cardioversion of atrial fibrillation. In: Falk RH, Podrid PJ, editors. Atrial fibrillation: mechanisms and management. New York: Raven Press, 1992: 181-96

  86. Metcalfe MJ, Smith F, Jennings K, et al. Does cardioversion of atrial fibrillation result in myocardial damage?. BMJ 1988; 296: 1364

    Article  PubMed  CAS  Google Scholar 

  87. Van Gelder IC, Crijns HJ, Van Der Laarse A, et al. Incidence and clinical significance of ST segment elevation after electrical cardioversion of atrial fibrillation and atrial flutter. Am Heart J 1991; 121: 51–6

    Article  PubMed  Google Scholar 

  88. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC cardioversion of atrial fibrillation. Am J Cardiol 1969; 23: 208–15

    Article  PubMed  CAS  Google Scholar 

  89. Arnold AZ, Mick MJ, Mazurek RP, et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19: 851–5

    Article  PubMed  CAS  Google Scholar 

  90. Grimm RA, Stewart WJ, Black IW, et al. Should all patients undergo transesophageal echocardiography before electrical cardioversion of atrial fibrillation?. J Am Coll Cardiol 1994; 23: 533–41

    Article  PubMed  CAS  Google Scholar 

  91. Manning WJ, Silverman DI, Gordon SPF, et al. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993; 328: 750–5

    Article  PubMed  CAS  Google Scholar 

  92. Grimm RA, Stewart WJ, Maloney JD, et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993; 22: 1359–66

    Article  PubMed  CAS  Google Scholar 

  93. Black IW, Grimm RA, Walsh WF, et al. Risk factors for atrial thrombus and stroke in 156 patients undergoing electrical cardioversion: a multicenter transesophageal echocardiographic study. J Am Coll Cardiol 1993; 21 Suppl.A: 28A

    Google Scholar 

  94. Fatkin D, Kuchar D, Thorburn C, et al. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for ‘atrial stunning’ as a mechanism of thromboembolic complications. J Am Coll Cardiol 1993; 21 Suppl.A: 28A

    Google Scholar 

  95. Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes: evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 1993; 73: 1061–76

    Article  PubMed  CAS  Google Scholar 

  96. Lewis T. The value of quinidine in cases of auricular fibrillation and methods of studying the clinical reaction. Am J Med Sci 1922; 163: 781–94

    CAS  Google Scholar 

  97. Parkinson J, Campbell M. The quinidine treatment of auricular fibrillation. Q J Med 1929; 22: 281–303

    CAS  Google Scholar 

  98. Viko LE, Marvin HM, White PD. A clinical report on the use of quinidin sulphate. Arch Int Med 1923; 31: 345–63

    Article  Google Scholar 

  99. Sokolow M, Edgar AL. Blood quinidine concentrations as a guide in the treatment of cardiac arrhythmias. Circulation 1950; 1: 576–92

    Article  Google Scholar 

  100. Halpern SW, Ellrodt G, Singh BN, et al. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: relation to left atrial size. Br Heart J 1980; 44: 589–95

    Article  PubMed  CAS  Google Scholar 

  101. Fenster PE, Comess KA, Marsh R, et al. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983; 106: 501–4

    Article  PubMed  CAS  Google Scholar 

  102. Fujimura O, Klein GJ, Sharma AD, et al. Acute effect of dis-opyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1989; 13: 1133–7

    Article  PubMed  CAS  Google Scholar 

  103. Goy JJ, Maendly R, Grbic M, et al. Cardioversion with flecainide in patients with atrial fibrillation of recent onset [letter]. Eur J Clin Pharmacol 1985; 27: 737–8

    Article  PubMed  CAS  Google Scholar 

  104. Crijns HJGM, van Wijk LM, van Gilst WH, et al. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988; 9: 634–8

    CAS  Google Scholar 

  105. Goy JJ, Kaufmann U, Kappenberger L, et al. Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. Am J Cardiol 1988; 62: 38D–40D

    Article  PubMed  CAS  Google Scholar 

  106. Borgeat A, Goy JJ, Maendly R, et al. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986; 58: 496–8

    Article  PubMed  CAS  Google Scholar 

  107. Suttorp MJ, Kingma JH, Lie-A-Huen L, et al. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989; 63: 693–6

    Article  PubMed  CAS  Google Scholar 

  108. Kondili A, Kastrati A, Popa Y. Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. Wiener Klinische Wochenschrift 1990; 17: 510–3

    Google Scholar 

  109. Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722–7

    Article  PubMed  CAS  Google Scholar 

  110. Bianconi L, Boccadamo R, Pappalardo A, et al. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989; 64: 335–8

    Article  PubMed  CAS  Google Scholar 

  111. Cowan JC, Gardiner P, Reid DS, et al. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction. J Car-diovasc Pharmacol 1986; 8: 252–6

    Article  CAS  Google Scholar 

  112. Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 1990; 65: 679–80

    Article  PubMed  CAS  Google Scholar 

  113. Pilati G, Lenzi T, Trisolino G, et al. Amiodarone versus quini-dine for conversion of recent onset atrial fibrillation to sinus rhythm. Current Therapeutic Research 1991; 49: 140–6

    Google Scholar 

  114. Nattel S, Talajic M, Fermini B, et al. Amiodarone: pharmacology, clinical actions, and relationships between them. J Car-diovasc Electrophysiol 1992; 3: 266–80

    Article  Google Scholar 

  115. Nattel S, Zeng FD. Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1984; 229: 283–91

    PubMed  CAS  Google Scholar 

  116. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81: 686–90

    Article  PubMed  CAS  Google Scholar 

  117. Singh BN, Nademanee K. Sotalol: a beta blocker with unique antiarrhythmic properties. Am Heart J 1987; 114: 121–39

    Article  PubMed  CAS  Google Scholar 

  118. Suttorp MJ, Polak PE, van Hof A, et al. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol 1992; 69: 417–9

    Article  PubMed  CAS  Google Scholar 

  119. Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med 1987; 106: 503–6

    PubMed  CAS  Google Scholar 

  120. Waxman HL, Myerburg RJ, Appel R, et al. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter. Ann Intern Med 1981; 94: 1–6

    PubMed  CAS  Google Scholar 

  121. Anderson S, Blanski L, Byrd RC, et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am Heart J 1986; 111: 42–8

    Article  PubMed  CAS  Google Scholar 

  122. Bath JCJL. Treatment of cardiac arrhythmias in unanesthetized patients: role of adrenergic beta receptor blockade. Am J Cardiol 1966; 18: 415–25

    Article  PubMed  CAS  Google Scholar 

  123. Gibson D, Sowton E. The use of beta adrenergic receptor blocking drugs in dysrhythmias. Prog Cardiovasc Dis 1964; 12: 16–39

    Article  Google Scholar 

  124. Andrews TC, Reimold SC, Berlin JA, et al. Prevention of supraventricular arrhythmias after coronary artery bypass surgery: a meta-analysis of randomized control trials. Circulation 1991; 84 Suppl. III: III236-44

  125. Kowey PR, Taylor JE, Rials SJ, et al. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol 1992; 69: 963–4

    Article  PubMed  CAS  Google Scholar 

  126. Campbell TJ, Gavaghan TP, Morgan JJ. Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass: comparison with disopyramide and digoxin in a randomised trial. Br Heart J 1985; 54: 86–90

    Article  PubMed  CAS  Google Scholar 

  127. Limberg L, Castellanos A, Arcebal A. The use of propranolol in arrhythmias complicating acute myocardial infarction. Am Heart J 1970; 80: 479–87

    Article  Google Scholar 

  128. Allen JD, Pantridge JF, Shanks DG. The effects of practotol on the dysrhythmias complicating acute ischemic heart disease. Am J Med 1975; 58: 199–208

    Article  PubMed  CAS  Google Scholar 

  129. Jewett DE, Singh BN. Role of beta adrenergic blockade in myocardial infarction. Prog Cardiovasc Dis 1974; 16: 421–38

    Article  Google Scholar 

  130. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989; 63: 925–9

    Article  PubMed  CAS  Google Scholar 

  131. Boissel JP, Wolf E, Gillet J, et al. Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J 1981; 2: 49–55

    PubMed  CAS  Google Scholar 

  132. Byrne-Quinn E, Wing AJ. Maintenance of sinus rhythm after DC reversion of atrial fibrillation. Br Heart J 1970; 32: 370–6

    Article  PubMed  CAS  Google Scholar 

  133. Edhag O, Erhardt LR, Lundman T, et al. Verapamil and quinidine in maintaining sinus rhythm after electroconversion of atrial fibrillation. Opuscula Medica 1982; 27: 22–4

    Google Scholar 

  134. Gunning JF, Kristinsson A, Miller G, et al. Long-term follow-up of direct current cardioversion after cardiac surgery with special reference to quinidine. Br Heart J 1970; 32: 462–6

    Article  PubMed  CAS  Google Scholar 

  135. Hall JI, Wood DR. Factors affecting cardioversion of atrial arrhythmias with special reference to quinidine. Br Heart J 1968; 30: 84–90

    Article  PubMed  CAS  Google Scholar 

  136. Härtel G, Louhija A, Konttinen A, et al. Value of quinidine in maintenance of sinus rhythm after electric cardioversion of atrial fibrillation. Br Heart J 1970; 32: 57–60

    Article  PubMed  Google Scholar 

  137. Hillestad L, Bjerkelund C, Dale J, et al. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation: a controlled clinical study. Br Heart J 1971; 33: 518–21

    Article  PubMed  CAS  Google Scholar 

  138. Lloyd EA, Gersh BJ, Forman R. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation: a double-blind study comparing quinidine, disopyramide and placebo. S Afr Med J 1984; 65: 367–9

    PubMed  CAS  Google Scholar 

  139. Radford MD, Evans DW. Long term results of DC reversion of atrial fibrillation. Br Heart J 1968; 30: 91–6

    Article  PubMed  CAS  Google Scholar 

  140. Rasmussen K, Wang H, Fausa D. Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation: a controlled clinical trial. Acta Med Scand 1981; Suppl. 645: 23-8

  141. Södermark T, Edhag O, Sjögren, et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter: a multicenter study from Stockholm. Br Heart J 1975; 37: 486–92

    Article  PubMed  Google Scholar 

  142. Härtel G, Louhija A, Konttinen A. Disopyramide in the prevention of atrial fibrillation after electroconversion. Clin Pharm Ther 1974; 15: 551–5

    Google Scholar 

  143. Karlson BW, Torstensson I, Åbjörn C, et al. Disopyramide in the maintenance of sinus rhythm after electrocardioversion of atrial fibrillation: a placebo controlled one-year follow-up study. Eur Heart J 1988; 9: 284–90

    PubMed  CAS  Google Scholar 

  144. Rasmussen K, Andersen A, Abrahamsen AM, et al. Flecainide versus disopyramide in maintaining sinus rhythm following conversion of chronic atrial fibrillation [abstract]. Eur Heart J 1988; 9 Suppl.1: 52

    Google Scholar 

  145. Touboul P, Aliot E, Brembilla-Perrot B. Flecainide in the prevention of atrial fibrillation after cardioversion: comparison with quinidine. Circulation 1991; 84: II127

    Google Scholar 

  146. Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989; 64: 1317–21

    Article  PubMed  Google Scholar 

  147. Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation. Circulation 1990; 82: 1932–9

    Article  PubMed  Google Scholar 

  148. Reimold SC, Cantillon CO, Friedman PL, et al. Propafenone versus Sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71: 558–63

    Article  PubMed  CAS  Google Scholar 

  149. Antman EM, Beamer AD, Cantillon C, et al. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 12: 1005–11

    Article  PubMed  CAS  Google Scholar 

  150. Vitolo E, Tronci M, Larovere MT, et al. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981; 36: 431–44

    PubMed  CAS  Google Scholar 

  151. Antman EM, Beamer AD, Cantillon C, et al. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15: 698–707

    Article  PubMed  CAS  Google Scholar 

  152. Crijns HJ, Van Gelder IC, Van Gilst WH, et al. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68: 335–41

    Article  PubMed  CAS  Google Scholar 

  153. Brodsky MA, Allen BJ, Capparelli EV, et al. Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am J Cardiol 1989; 63: 1065–8

    Article  PubMed  CAS  Google Scholar 

  154. Ewy G, Ulfers L, Hager WD, et al. Response of atrial fibrillation to therapy: role of etiology and left atrial diameter. J Elec-trocardiol 1980; 13: 119–24

    CAS  Google Scholar 

  155. Flugelman MY, Hasin Y, Katznelson N, et al. Restoration and maintenance of sinus rhythm after mitral valve surgery for mitral stenosis. Am J Cardiol 1984; 54: 617–9

    Article  PubMed  CAS  Google Scholar 

  156. Henry WL, Morganroth J, Pearlman AS, et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976; 53: 273–9

    Article  PubMed  CAS  Google Scholar 

  157. Dethy M, Chassat C, Roy D, et al. Doppler echocardiograhic predictors of recurrence of atrial fibrillation after cardioversion. Am J Cardiol 1988; 62: 723–6

    Article  PubMed  CAS  Google Scholar 

  158. Dittrich HC, Erickson JS, Schneiderman T, et al. Echocardio-graphic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989; 63: 193–7

    Article  PubMed  CAS  Google Scholar 

  159. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82: 1106–16

    Article  PubMed  CAS  Google Scholar 

  160. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527–32

    Article  PubMed  CAS  Google Scholar 

  161. Greene HL, Roden DM, Katz RJ, et al. The cardiac arrhythmia suppression trial: first CAST… then CAST-II. J Am Coll Cardiol 1992; 19: 894–8

    CAS  Google Scholar 

  162. Nattel S, Talajic M. Recent advances in understanding the pharmacology of amiodarone. Drugs 1988; 36: 121–31

    Article  PubMed  CAS  Google Scholar 

  163. Graboys TB, Podrid PJ, Lown B. Efficacy of amiodarone for refractory supraventracular tachyarrhythmias. Am Heart J 1983; 106: 870–6

    Article  PubMed  CAS  Google Scholar 

  164. Horowitz LN, Speilman SR, Greenspan AM, et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985; 6: 1402–7

    Article  PubMed  CAS  Google Scholar 

  165. Brodsky MA, Allen BJ, Walker III CJ, et al. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J. Cardiol 1987; 60: 572–5

    Article  PubMed  CAS  Google Scholar 

  166. Gosselink ATM, Crijns HJGM, Van Gelder IC, et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267: 3289–93

    Article  PubMed  CAS  Google Scholar 

  167. Gold RL, Haffajee CI, Charos G, et al. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57: 124–7

    Article  PubMed  CAS  Google Scholar 

  168. Blevins RD, Kerin NZ, Benaderet D, et al. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 1987; 147: 1401–4

    Article  PubMed  CAS  Google Scholar 

  169. Crijns HJGM, Gosselink ATM, van Gelder IC, et al. Drugs after cardioversion to prevent relapses of chronic atrial fibrillation or flutter. In: Kingma JH, van Hemel NM, Lie KI, editors. Atrial fibrillation, a treatable disease? Netherlands: Kluwer Academic Publishers, 1992: 105-48

  170. Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current. J Gen Physiol 1990; 96: 195–214

    Article  PubMed  CAS  Google Scholar 

  171. Sanguinetti MC, Jurkiewicz NK. Delayed rectifier outward K+ current is composed of two currents in guinea pig atrial cells. Am J Physiol 1991; 260: H393–9

    PubMed  CAS  Google Scholar 

  172. Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent: specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 1993; 72: 75–83

    Article  PubMed  CAS  Google Scholar 

  173. Nattel S, Quantz MA. Pharmacological response of quinidine induced early after depolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc Res 1988; 22: 808–17

    Article  PubMed  CAS  Google Scholar 

  174. Roden DM, Hoffman BE. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: relationship to potassium and cycle length. Circ Res 1985; 56: 857–67

    Article  PubMed  CAS  Google Scholar 

  175. Baiser JR, Hondeghem LM, Roden DM. Suppression of time-dependent outward current in guinea pig ventricular myocytes: actions of quinidine and amiodarone. Circ Res 1991; 69: 519–29

    Article  Google Scholar 

  176. Zhang Z, Follmer CH, Sarma JSM, et al. Effect of ambasilide, a new class III agent, on plateau currents in isolated guinea pig ventricular myocytes: block of delayed outward potassium current. J Pharmacol Exp Ther 1992; 263: 40–8

    PubMed  CAS  Google Scholar 

  177. Sager PT, Uppal P, Follmer C, et al. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993; 88: 1063–71

    Article  PubMed  CAS  Google Scholar 

  178. Nattel S, Wang Z, Fermini B. Three types of delayed rectifier potassium currents in human atrial cardiomyocytes [abstract]. Biophys J 1993; 64: A393

    Google Scholar 

  179. Busch AE, Malloy KJ, Varnum MD, et al. A slowly-activating potassium current IKS is the target for the class III antiarrhythmic drug NE-10064 [abstract]. Circulation 1993; 882: 1231

    Google Scholar 

  180. Fedida D, Wible B, Wang Z, et al. Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ Res 1993; 73: 210–6

    Article  PubMed  CAS  Google Scholar 

  181. Tamkun MM, Knoth KM, Walbridge JA, et al. Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle. FASEB J 1991; 5: 331–7

    PubMed  CAS  Google Scholar 

  182. Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115–72

    Article  PubMed  CAS  Google Scholar 

  183. Lynch JJ, DiCarlo LA, Montgomery DG, et al. Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. Pharmacology 1987; 35: 181–93

    Article  PubMed  CAS  Google Scholar 

  184. Ranger S, Nattel S. Rate-dependent transverse conduction block and flecainide proarrhythmia in infarcted hearts. Circulation 1993; 88 Suppl.1: 131

    Google Scholar 

  185. Zimmerman JM, Bigger JT Jr, Coromilas J. Flecainide acetate is arrhythmogenic in a canine model of sustained ventricular tachycardia [abstract]. J Am Coll Cardiol 1985; 5: 391

    Google Scholar 

  186. Elharrar V, Gaum WE, Zipes DR. Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. Am J Cardiol 1977; 39: 544–9

    Article  PubMed  CAS  Google Scholar 

  187. Nattel S, Pederson DH, Zipes DP. Alterations in regional myocardial distribution and arrhythmogenic effects of aprinidine produced by coronary artery occlusion in the dog. Cardiovasc Res 1981; 15: 80–5

    Article  PubMed  CAS  Google Scholar 

  188. Bigger Jr JT, Sahar DI. Clinical types of proarrhythmic response to antiarrhythmic drugs. Am J Cardiol 1987; 59: 2E–9E

    Article  PubMed  Google Scholar 

  189. Levine JH, Morganroth J, Kadish AH. Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy. Circulation 1989; 80: 1063–9

    Article  PubMed  CAS  Google Scholar 

  190. Feld GK, Chen PS, Nicod P, et al. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 1990; 66: 378–83

    Article  PubMed  CAS  Google Scholar 

  191. Murdock CJ, Kyles AE, Yeung-Lai-Wah JA, et al. Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990; 66: 755–7

    Article  PubMed  CAS  Google Scholar 

  192. Nayebpour M, Talajic M, Villemaire C, et al. An animal model of propafenone-induced atrial proarrhythmia [abstract]. J Am Coll Cardiol 1994; special issue: 206A

  193. Podrid PJ. Oral antiarrhythmic drugs used for atrial fibrillation: clinical pharmacology. In: Falk RH, Podrid PJ, editors. Atrial fibrillation: mechanisms and management. New York: Raven Press, 1992: 197-231

  194. Roden DM. Treatment of cardiovascular disorders: arrhythmias. In: Melmon KL, Morrelli HF, Hoffman BB, et al., editors. Clinical pharmacology. Basic principles in therapeutics. 3rd ed. New York: McGraw-Hill Inc., 1992: 151-85

  195. Williams JM, Ungerleider RM, Lofland GK, et al. Left atrial isolation: new technique for the treatment of supraventricular arrhythmias. J Thorac Cardiovasc Surg 1980; 80: 373–80

    PubMed  CAS  Google Scholar 

  196. Guiraudon GM, Campbell CS, Jones DL, et al. Combined sinoatrial node atrio-ventricular isolation: a surgical alternative to His bundle ablation in patients with atrial fibrillation [abstract]. Circulation 1985; 72 Suppl.3: 220

    Google Scholar 

  197. van Hemel NM, Defauw JJAMT, Kingma JH, et al. Long-term results of the corridor operation for atrial fibrillation. Br Heart J 1994; 71: 170–6

    Article  PubMed  Google Scholar 

  198. Cox JL, Boineau JP, Schuessler RB, et al. Successful surgical treatment of atrial fibrillation: review and clinical update. JAMA 1991; 266: 1976–80

    Article  PubMed  CAS  Google Scholar 

  199. McCarthy PM, Castle LW, Maloney JD, et al. Initial experience with the maze procedure for atrial fibrillation. J Thorac Cardiovasc Surg 1993; 105: 1077–87

    PubMed  CAS  Google Scholar 

  200. Klein LS, Miles WM, Zipes DP. Antitachycardia devices: realities and promises. J Am Coll Cardiol 1991; 18: 1349–62

    Article  PubMed  CAS  Google Scholar 

  201. Levy S, Lacombe P, Cointe R, et al. High energy transcatheter cardioversion of chronic atrial fibrillation. J Am Coll Cardiol 1988; 12: 514–8

    Article  PubMed  CAS  Google Scholar 

  202. Levy S, Lauribe P, Dolla E, et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992; 86: 1415–20

    Article  PubMed  CAS  Google Scholar 

  203. Powell AC, Garan H, McGovern BA, et al. Low energy conversion of atrial fibrillation in the sheep. J Am Coll Cardiol 1992; 20: 707–11

    Article  PubMed  CAS  Google Scholar 

  204. Murgatroyd FD, Slade AKB, O’Farrell DM, et al. Transvenous low-energy cardioversion of short-duration atrial fibrillation in humans [abstract]. J Am Coll Cardiol 1994; special issue: 126A

  205. Saksena S, Mongeon L, Krol R, et al. Clinical efficacy and safety of atrial defibrillation using current nonthoracotomy endocardial lead configurations: a prospective randomized study [abstract]. J Am Coll Cardiol 1994; 125A

  206. Gosselink ATM, Bijlsma EB, Landsman MLJ, et al. Long-term effect of cardioversion on peak oxygen consumption in chronic atrial fibrillation: a 2 years follow-up [abstract]. J Am Coll Cardiol 1994; special issue: 250A

  207. Hammond K, Froelicher VF. Normal and abnormal heart rate responses to exercise. Prog Cardiovasc Dis 1985; 28: 271–96

    Article  Google Scholar 

  208. Hoffman BE The pharmacology of cardiac glycosides. In: Rosen MR, Hoffman BF, editors. Cardiac therapy. The Hague: Martinus Nijhoff Publishers, 1983: 387-412

  209. Goldman S, Probst P, Selzer A, et al. Inefficacy of therapeutic serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol 1975; 35: 651–5

    Article  PubMed  CAS  Google Scholar 

  210. Blumgart H. The reaction to exercise of the heart affected by auricular fibrillation. Heart 1924; 11: 49–56

    Google Scholar 

  211. Knox JAC. The heart rate with exercise patients with auricular fibrillation. Br Heart J 1949; 11: 119–25

    Article  PubMed  CAS  Google Scholar 

  212. Modell W, Gold H, Rothendler HH. Use of digitalis to prevent exaggerated acceleration of the heart. JAMA 1941; 116: 2241–4

    Article  Google Scholar 

  213. Redfors A. Digoxin dosage and ventricular rate at rest and exercise in patients with atrial fibrillation. Acta Med Scand 1971; 190: 321–33

    Article  PubMed  CAS  Google Scholar 

  214. Galun E, Flugelman MY, Glickson M, et al. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest 1991; 99: 1038–40

    Article  PubMed  CAS  Google Scholar 

  215. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990; 63: 225–7

    Article  PubMed  CAS  Google Scholar 

  216. DiBianco R, Morganroth J, Freitag RJ, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate in patients with chronic atrial fibrillation receiving stable doses of digoxin. Am Heart J 1984; 108: 1121–7

    Article  PubMed  CAS  Google Scholar 

  217. Atwood JE, Sullivan M, Forbes S, et al. Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 1987; 10: 314–20

    Article  PubMed  CAS  Google Scholar 

  218. Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter: the diltiazem-atrial fibrillation/flutter study group. Am J Cardiol 1989; 63: 1046–51

    Article  PubMed  CAS  Google Scholar 

  219. Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol 1991; 18: 891–7

    Article  PubMed  CAS  Google Scholar 

  220. Heywood JT, Graham B, Marais GE, et al. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. Am J Cardiol 1991; 67: 1150–2

    Article  PubMed  CAS  Google Scholar 

  221. Roth A, Harrison E, Mitani G, et al. Efficacy of medium and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986; 73: 316–24

    Article  PubMed  CAS  Google Scholar 

  222. Lang R, Klein H, Segni E, et al. Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study. Am Heart J 1983; 105: 820–4

    Article  PubMed  CAS  Google Scholar 

  223. Lang R, Klein HO, Weiss E, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 1983; 83: 491–9

    Article  PubMed  CAS  Google Scholar 

  224. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16: 86–90

    Article  PubMed  CAS  Google Scholar 

  225. Atwood JE, Myers JN, Sullivan MJ, et al. Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest 1988; 93: 20–5

    Article  PubMed  CAS  Google Scholar 

  226. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 1970; 39: 657–67

    Article  PubMed  CAS  Google Scholar 

  227. Nattel S, Talajic M, Quantz M, et al. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity. Circulation 1987; 76: 442–9

    Article  PubMed  CAS  Google Scholar 

  228. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol 1970; 39: 668–77

    Article  PubMed  CAS  Google Scholar 

  229. Perelman MS, McKenna WJ, Rowland E, et al. A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. Br Heart J 1987; 58: 339–44

    Article  PubMed  CAS  Google Scholar 

  230. Huang SKS. Advances in applications of radiofrequency current to catheter ablation therapy. PACE 1991; 14: 28–42

    Article  PubMed  CAS  Google Scholar 

  231. Blanck Z, Dhala A, Krum D, et al. Dramatic reduction in ventricular response during atrial fibrillation by ablating the atrioventricular nodal slow pathway: electrophysiologic and clinical implications [abstract]. Circulation 1993; 88: 1584

    Google Scholar 

  232. Feld GK, Fujimura O, Fleck PR, et al. Radiofrequency catheter modification of the AV node for control of rapid ventricular response to atrial fibrillation [abstract]. Circulation 1993; 88: I–584

    Google Scholar 

  233. Peterson P. Thromboembolic complications in atrial fibrillation. Stroke 1990; 21: 4–13

    Article  Google Scholar 

  234. Sherman DG, Goldman L, Whiting RR, et al. Thromboembolism in patients with atrial fibrillation. Arch Neurol 1984; 41: 708–10

    Article  PubMed  CAS  Google Scholar 

  235. Roy D, Marchand E, Gagne P, et al. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986; 112: 1139–43

    Article  Google Scholar 

  236. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–11

    Article  Google Scholar 

  237. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349–55

    Article  PubMed  CAS  Google Scholar 

  238. Peterson P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989; 1: 175–9

    Article  Google Scholar 

  239. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: 527–39

    Article  Google Scholar 

  240. Veterans’ Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406–12

    Article  Google Scholar 

  241. Walker MD. Atrial fibrillation and anti-thrombotic prophylaxis: a prospective meta-analysis. Lancet 1989; 1: 325–6

    Article  PubMed  CAS  Google Scholar 

  242. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 687–91

    Google Scholar 

  243. DeSilva RA, Graboys TB, Podrid PJ, et al. Cardioversion and defibrillation. Am Heart J 1980; 100: 881–95

    Article  PubMed  CAS  Google Scholar 

  244. Mancini GB, Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker and long-term success. Am Heart J 1982; 104: 617–21

    Article  PubMed  CAS  Google Scholar 

  245. Manning WJ, Leeman DE, Gotch PJ, et al. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol 1989; 13: 617–23

    Article  PubMed  CAS  Google Scholar 

  246. Shenasa M, Kus T, Fromer M, et al. Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. Am J Cardiol 1988; 62: 403–7

    Article  PubMed  CAS  Google Scholar 

  247. Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic reccurences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989; 80: 1557–70

    Article  PubMed  CAS  Google Scholar 

  248. van Wijk LM, den Heijer P, Crijns HJ, et al. Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol 1989; 13: 32–6

    Article  PubMed  Google Scholar 

  249. Lau CP, Leung WH, Wong CK. A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. Am Heart J 1992; 124: 645–50

    Article  PubMed  CAS  Google Scholar 

  250. Antman EM, Beamer AD, Cantillon C, et al. Long-term oral propafenone for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 12: 1005–11

    Article  PubMed  CAS  Google Scholar 

  251. Leclercq JF, Chouty F, Denjoy I, et al. Flecainide in quinidine-resistant atrial fibrillation. Am J Cardiol 1992; 70: 62A–5A

    Article  PubMed  CAS  Google Scholar 

  252. Torner PM. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur Heart J 1991; 12: 144–52

    Google Scholar 

  253. Wellens HJJ, Durrer D. Effect of digitalis on atrioventricular conduction and circus movement tachycardias in patients with the Wolff-Parkinson-White syndrome. Circulation 1973; 47: 1229–33

    Article  PubMed  CAS  Google Scholar 

  254. Jackman W, Wang X, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991; 324: 1605–11

    Article  PubMed  CAS  Google Scholar 

  255. Fuller JA, Adams GC, Buxton B. Atrial fibrillation after coronary artery bypass grafting: is it a disorder of the elderly?. J Thorac Cardiovasc Surg 1989; 97: 821–5

    PubMed  CAS  Google Scholar 

  256. Taylor GJ, Malik SA, Colliver JA, et al. Usefulness of atrial fibrillation as a predictor of stroke after isolated coronary artery bypass grafting. Am J Cardiol 1987; 60: 905–7

    Article  PubMed  CAS  Google Scholar 

  257. Salazar C, Frishman W, Friedman S, et al. Beta-blockade therapy for supraventricular tachyarrhythmias after coronary surgery: a propranolol withdrawal syndrome?. Angiology 1979; 30: 816–9

    Article  PubMed  CAS  Google Scholar 

  258. Schwartz M, Michelson EL, Savin HS, et al. Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias. Chest 1988; 93: 705–11

    Article  PubMed  CAS  Google Scholar 

  259. Connolly SJ, Mulji AS, Hoffert DL, et al. Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. J Am Coll Cardiol 1987; 10: 1145–8

    Article  PubMed  CAS  Google Scholar 

  260. McAlister HF, Luke RA, Whitlock RM, et al. Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations. J Thorac Cardiovasc Surg 1990; 99: 911–8

    PubMed  CAS  Google Scholar 

  261. Cristal N, Szwarcberg J, Gueron M. Supraventricular arrhythmias in acute myocardial infarction-prognostic importance of clinical setting; mechanism of production. Ann Intern Med 1975; 82: 35–9

    PubMed  CAS  Google Scholar 

  262. Fluch D, Olsar E, Pentecost BL, et al. Natural history and clinical significance of arrhythmias after acute myocardial infarction. Br Heart J 1967; 29: 170–89

    Article  Google Scholar 

  263. Jewitt DE, Balcon R, Raffery EB, et al. Incidence and management of supraventricular arrhythmias after acute myocardial infarction. Lancet 1967; 2: 734–8

    Article  PubMed  CAS  Google Scholar 

  264. Goldberg RJ, Seeley D, Becker RC, et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1990; 119: 996–1001

    Article  PubMed  CAS  Google Scholar 

  265. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 57-65

  266. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187–92

    Article  PubMed  CAS  Google Scholar 

  267. Pollak A, Falk RH. Pacemaker therapy in patients with atrial fibrillation. Am Heart J 1993; 125: 824–30

    Article  PubMed  CAS  Google Scholar 

  268. Feuer JM, Shandling AH, Messenger JC. Influence of cardiac pacing mode on the long-term development of atrial fibrillation. Am J Cardiol 1989; 64: 1376–9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Montreal Heart Institute and University of Montreal, 5000 Belanger Street East, Montreal, Quebec, HIT 1C8, Canada

    Stanley Nattel, Tommy Hadjis & Mario Talajic

  2. Department of Pharmacology and Therapeutics, McGill University, Montreal, Montreal, Quebec, Canada

    Stanley Nattel

Authors
  1. Stanley Nattel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tommy Hadjis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario Talajic
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nattel, S., Hadjis, T. & Talajic, M. The Treatment of Atrial Fibrillation. Drugs 48, 345–371 (1994). https://doi.org/10.2165/00003495-199448030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199448030-00003

Keywords

Search

Navigation